文献速递糖尿病肥胖与代谢综合征

SELECT研究中司美格鲁肽对超重或肥胖但无糖尿病者心血管结局的作用:按基线HbA1c和HbA1c变化分析

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
PubMed 文献 · Diabetes Care · 2024-01-01

SELECT研究预设分析纳入17,604例超重或肥胖合并动脉粥样硬化性心血管疾病但无糖尿病者,随机接受每周司美格鲁肽2.4 mg或安慰剂。司美格鲁肽较安慰剂使首次主要不良心血管事件(MACE)降低20%,此效应在各基线HbA1c亚组及HbA1c变化亚组中一致,全因死亡除外。

要点

  • 司美格鲁肽2.4 mg每周一次使超重或肥胖合并ASCVD但无糖尿病者首次MACE降低20%。
  • 心血管获益在各基线HbA1c亚组(<5.7%、5.7%至<6.0%、6.0%至<6.5%)间未见差异。
  • 心血管结局在各HbA1c变化亚组(<-0.3、-0.3至0.3、>0.3个百分点)间也一致。

核心结论

  • 在超重或肥胖且已确诊动脉粥样硬化性心血管疾病但无糖尿病者中,司美格鲁肽降低心血管事件,与基线HbA1c或HbA1c变化无关。
  • 因此,司美格鲁肽预计对基线血糖正常和/或HbA1c未改善的已确诊动脉粥样硬化性心血管疾病者具有心血管获益。

研究设计与样本

  • SELECT研究为预设分析,将超重或肥胖合并动脉粥样硬化性心血管疾病但无糖尿病者随机分配至每周司美格鲁肽2.4 mg或安慰剂组。
  • 分析采用意向性治疗原则和Cox比例风险模型,按基线HbA1c亚组及基线至20周HbA1c变化类别(<-0.3、-0.3至0.3、>0.3个百分点)评估结局。
  • 共纳入17,604例参与者,平均年龄61.6岁,男性占72.3%。

主要发现

  • 司美格鲁肽较安慰剂使首次MACE(心血管死亡、非致死性心肌梗死或卒中)降低20%。
  • 基线HbA1c分布:<5.7%者占33.5%,5.7%至<6.0%者占34.6%,6.0%至<6.5%者占31.9%。
  • 司美格鲁肽较安慰剂的心血管风险降低在各基线HbA1c组间未显示不同,且除全因死亡外所有终点与总体研究一致。
  • 心血管结局在各HbA1c变化亚组间也一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT). RESEARCH DESIGN AND METHODS: In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo. The primary end point of first major adverse cardiovascular event (MACE) (cardiovascular mortality, nonfatal myocardial infarction, or stroke) was reduced by 20% with semaglutide versus placebo. Analysis of outcomes included first MACE, its individual components, expanded MACE (cardiovascular mortality, nonfatal myocardial infarction, or stroke; coronary revascularization; or hospitalization for unstable angina), a heart failure composite (heart failure hospitalization or urgent medical visit or cardiovascular mortality), coronary revascularization, and all-cause mortality by baseline HbA1c subgroup and categories of HbA1c change (<-0.3, -0.3 to 0.3, and >0.3 percentage points) from baseline to 20 weeks using the intention-to-treat principle with Cox proportional hazards. RESULTS: Among 17,604 participants (mean age 61.6 years, 72.3% male), baseline HbA1c was <5.7% for 33.5%, 5.7% to <6.0% for 34.6%, and 6.0% to <6.5% for 31.9%. Cardiovascular risk reduction with semaglutide versus placebo was not shown to be different across baseline HbA1c groups and was consistent with that of the overall study for all end points, except all-cause mortality. Cardiovascular outcomes were also consistent across subgroups of HbA1c change. CONCLUSIONS: In people with overweight or obesity and established atherosclerotic cardiovascular disease but not diabetes, semaglutide reduced cardiovascular events irrespective of baseline HbA1c or change in HbA1c. Thus, semaglutide is expected to confer cardiovascular benefits in people with established atherosclerotic cardiovascular disease who are normoglycemic at baseline and/or in those without HbA1c improvements.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lingvay I, Deanfield J, Kahn SE, et al. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024. PMID: 38907684. doi:10.2337/dc24-0764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。